Abstract: The present invention relates to a composition for an organic optoelectronic device, the composition comprising: a first host compound represented by Chemical Formula 1 below; and a second host compound represented by Chemical Formula 2 below, to an organic optoelectronic device using the composition and a display device. The details of Chemical Formulas 1 and 2 above are as defined in the specification.

Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the compound according to the present disclosure, an organic electroluminescent device having improved driving voltage, power efficiency and/or lifetime characteristics compared to conventional organic electroluminescent devices can be provided.

Abstract: The present invention relates to a composition for an organic optoelectronic device, the composition comprising: a first host compound represented by Chemical Formula 1 below; and a second host compound represented by Chemical Formula 2 below, to an organic optoelectronic device using the composition and a display device. The details of Chemical Formulas 1 and 2 above are as defined in the specification.

Abstract: Disclosed are a compound represented by Chemical Formula 1, a composition comprising the same, an organic optoelectronic diode, and a display device. Chemical formula 1 is as defined in the specification.

Abstract: The present invention relates to a fusion protein including PD-L1 protein and a modified immunoglobulin Fc region and use thereof, and since the fusion protein has significantly higher purity and production yield compared to the existing fusion protein, has a high binding affinity to PD-1, reduces the proliferation of activated T cells, inhibits the generation of cytokines generated by activated T cells, and has an effect of inhibiting the infiltration of T cells or macrophages into tissues, it can be effectively used in the treatment of immune diseases.

Abstract: A display device includes a display structure including a display panel and a touch sensing layer disposed on the display panel, the display panel including a display panel including a display area and a non-display area around the display area, and the touch sensing layer including a first portion overlapping the display area and a second portion overlapping the non-display area, a window structure disposed on the display structure, a bonding layer disposed between the display structure and the window structure, and a touch flexible circuit board electrically connected with the touch sensing layer, wherein the touch flexible circuit board includes a first substrate member connected to the second portion, and a second substrate member provided with an ultraviolet (“UV”) transmitting member transmitting UV light emitted from a side of the bonding layer and extending from the first substrate member in a predetermined direction.

Abstract: The present invention relates to a fusion polypeptide containing a glucagon-like peptide (GLP) and an immunoglobulin hybrid Fc, and more specifically, to a fusion polypeptide with an increased half-life and improved efficacy compared to the conventional fusion polypeptide based on the discovery of an immunoglobulin hybrid Fc suitable for GLP or analogs thereof, and a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide. The fusion polypeptide of the present invention has an increased half-life and improved resistance to DPP-4 enzyme compared to those of GLP-1 and GLP-2, and it thus has improved drug efficacy in treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, compared to those of the conventional drugs.

Abstract: A display device includes a display structure including a display panel and a touch sensing layer disposed on the display panel, the display panel including a display panel including a display area and a non-display area around the display area, and the touch sensing layer including a first portion overlapping the display area and a second portion overlapping the non-display area, a window structure disposed on the display structure, a bonding layer disposed between the display structure and the window structure, and a touch flexible circuit board electrically connected with the touch sensing layer, wherein the touch flexible circuit board includes a first substrate member connected to the second portion, and a second substrate member provided with an ultraviolet (“UV”) transmitting member transmitting UV light emitted from a side of the bonding layer and extending from the first substrate member in a predetermined direction.

Abstract: The present invention relates to a fusion polypeptide containing a glucagon-like peptide (GLP) and an immunoglobulin hybrid Fc, and more specifically, to a fusion polypeptide with an increased half-life and improved efficacy compared to the conventional fusion polypeptide based on the discovery of an immunoglobulin hybrid Fc suitable for GLP or analogs thereof, and a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide. The fusion polypeptide of the present invention has an increased half-life and improved resistance to DPP-4 enzyme compared to those of GLP-1 and GLP-2, and it thus has improved drug efficacy in treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, compared to those of the conventional drugs.

Abstract: A light guide plate includes an upper surface, a lower surface facing the upper surface, a first side surface connecting the lower surface to the upper surface, the first side surface including an inclined surface defining an acute angle with respect to the upper surface, and a second side surface connecting the upper surface and the lower surface, the second side surface being a rounded surface and facing the first side surface.

Abstract: Disclosed is a human IgG4 Fc polypeptide variant, including a modified CH2 domain of human IgG4 Fc, wherein the modification contains a replacement of a 6-20 consecutive amino acid sequence from the N-terminus of the CH2 domain of IgG4 with a 4-18 consecutive amino acid sequence from the N-terminus of human IgA1 CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgA2 CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgD CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgE CH2, or a 4-18 consecutive amino acid sequence from the N-terminus of human IgM CH2. The Fc variant imparts to a biologically active polypeptide—the modified Fc variant with a prolonged in-vivo half-life and reduced immunogenic reaction.

Abstract: A liquid crystal display device includes a liquid crystal panel, an adhesive member on a lower surface of the liquid crystal panel, a light guide plate below the adhesive member, an optical sheet between the light guide plate and the liquid crystal panel and a dummy film between the light guide plate and the adhesive member, wherein the adhesive member is discontinuous in an area adjacent to the dummy film.

Abstract: A liquid crystal display device includes a liquid crystal panel, an adhesive member on a lower surface of the liquid crystal panel, a light guide plate below the adhesive member, an optical sheet between the light guide plate and the liquid crystal panel and a dummy film between the light guide plate and the adhesive member, wherein the adhesive member is discontinuous in an area adjacent to the dummy film.

Abstract: A light guide plate includes an upper surface, a lower surface facing the upper surface, a first side surface connecting the lower surface to the upper surface, the first side surface including an inclined surface defining an acute angle with respect to the upper surface, and a second side surface connecting the upper surface and the lower surface, the second side surface being a rounded surface and facing the first side surface.

Abstract: The present invention relates to aloe vera sprout concentrate or extract having cell growth promotion, antioxidant, and anti-allergy effects, and to a skin cell growth promoting, antioxidant, and anti-allergy pharmaceutical composition and functional health food or cosmetics containing the aloe vera sprout concentrate or extract as an active ingredient.